SignatureFD’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,750
| Closed | -$83.1K | – | 3412 |
|
|
2025
Q3 | $83.1K | Buy |
1,750
+137
| +8% | +$6.63K | ﹤0.01% | 1385 |
|
|
2025
Q2 | $86.1K | Sell |
1,613
-10
| -0.6% | -$454 | ﹤0.01% | 1308 |
|
|
2025
Q1 | $65.7K | Buy |
1,623
+45
| +3% | +$1.91K | ﹤0.01% | 1424 |
|
|
2024
Q4 | $43.9K | Hold |
1,578
| – | – | ﹤0.01% | 1654 |
|
|
2024
Q3 | $45.3K | Buy |
1,578
+58
| +4% | +$1.51K | ﹤0.01% | 1631 |
|
|
2024
Q2 | $35.7K | Buy |
1,520
+20
| +1% | +$428 | ﹤0.01% | 1679 |
|
|
2024
Q1 | $37.9K | Buy |
1,500
+17
| +1% | +$408 | ﹤0.01% | 1689 |
|
|
2023
Q4 | $34.6K | Sell |
1,483
-507
| -25% | -$10K | ﹤0.01% | 1653 |
|
|
2023
Q3 | $101K | Sell |
1,990
-9
| -0.5% | -$419 | ﹤0.01% | 1057 |
|
|
2023
Q2 | $93.3K | Sell |
1,999
-31
| -2% | -$1.42K | ﹤0.01% | 1098 |
|
|
2023
Q1 | $77.7K | Sell |
2,030
-142
| -7% | -$6.33K | ﹤0.01% | 1171 |
|
|
2022
Q4 | $119K | Buy |
2,172
+121
| +6% | +$5.18K | ﹤0.01% | 920 |
|
|
2022
Q3 | $70K | Buy |
2,051
+1,335
| +186% | +$20.4K | ﹤0.01% | 1121 |
|
|
2022
Q2 | $7K | Buy |
716
+595
| +492% | +$6.2K | ﹤0.01% | 2270 |
|
|
2022
Q1 | $2K | Buy |
+121
| New | +$2.12K | ﹤0.01% | 2761 |
|
|
2021
Q4 | – | Sell |
-48
| Closed | -$1K | – | 3092 |
|
|
2021
Q3 | $1K | Buy |
+48
| New | +$1.09K | ﹤0.01% | 2761 |
|
Other funds holding AKRO
SignatureFD's AKRO Position: Q4 2025 in Review
SignatureFD sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 1,750 shares — an estimated $83.1K sold.
SignatureFD first reported a position in AKRO in Q3 2021 and held it in 16 quarters. The position peaked at $119K in Q4 2022. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- SignatureFD reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- SignatureFD sold 1,750 Akero Therapeutics shares in Q4 2025, an estimated $83.1K.
- SignatureFD first reported a position in Akero Therapeutics in Q3 2021 and held it in 16 quarters.
- SignatureFD's Akero Therapeutics position peaked at $119K in Q4 2022.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on SignatureFD's 13F filing for Q4 2025, filed 20 Jan 2026.